Dr. Tareq Abadl: What If Blood Matching Went Deeper than Just ABO and Rh?
Dr. Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Precision Transfusion Medicine
What if blood matching went deeper than just ABO and Rh?
Molecular blood-group genotyping analyzes a patient’s blood-group genes to predict dozens of clinically significant antigens — transforming modern transfusion practice.
1. Deeper and Safer Matching
Genotyping identifies variant and weak alleles that routine serology may miss, such as:
Weak/Partial D variants
Rh, Kell, Kidd, Duffy, and MNS variants
This reduces the risk of alloimmunization, especially in patients requiring chronic transfusions (e.g., sickle cell disease, thalassemia).
2. Faster Compatible Unit Selection
Creating a genotyped donor registry allows rapid identification of best-matched units, which is crucial for patients with:
Multiple alloantibodies
Rare or complex phenotypes
3. Improved Antenatal Care
Molecular typing enhances:
Prediction of fetal antigen status
Early assessment of hemolytic disease of the fetus and newborn (HDFN)
Guidance on monitoring and intervention
4. Practical Limitations
Genotyping is powerful but works alongside serology, not as a replacement:
It predicts antigen expression, which may not always equal phenotype
Results can be affected after allogeneic stem-cell transplant or recent transfusion
Use buccal swabs or pre-transfusion samples when needed
Requires proper quality control and expert interpretation
5. Better Donor Strategy and Inventory
Molecular typing helps:
Recruit and flag rare-donor phenotypes
Improve blood-bank inventory management
Provide safer, more reliable matching for high-risk patients
How You Can Act
For Transfusion Professionals:
Implement targeted genotyping for chronically transfused or alloimmunized patients.
For Blood Donors:
Join local rare-donor programs if available — you may save lives in ways only a few can.
Find more posts featuring Dr. Tareq Abadl on Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits